Sevuparin dose-finding trial sets a pediatric ceiling for severe malaria support
Sevuparin has now crossed an important threshold in children with severe malaria: investigators identified a maximum tolerated dose of 3 mg/kg, delivered as three infusions at 0, 8 and 16 hours after enrolment. The finding comes from a phase I trial in Kenyan and Zambian children hospitalized with severe disease, where the dose-escalation design was built to watch closely for excessive anticoagulation, measured through activated partial thromboplastin time, or APTT.
The study is small, but the clinical problem it addresses is not. Severe malaria still fills pediatric wards across sub-Saharan Africa and continues to drive a large share of early hospital deaths, especially in children with cerebral malaria, profound anemia, or acidosis. The therapeutic logic behind sevuparin is simple enough to follow at the bedside: if parasite-infected erythrocytes can be detached from the microvasculature, blood flow may improve before organ injury deepens. In malaria, microvascular obstruction is not an abstract mechanism; it is the event that turns parasitemia into coma, lactic acidosis, and rapid deterioration.
Sevuparin is a heparin-like compound modified to remove the antithrombin-binding sequence that drives the anticoagulant effect of standard heparin. It still binds Plasmodium falciparum erythrocyte membrane protein 1, the parasite adhesion molecule central to sequestration and rosetting, but with markedly reduced impact on coagulation. That pharmacology matters in a disease where supportive treatment has to walk a narrow line: any agent intended to reverse sequestration must not create a bleeding hazard in already fragile children.
Dose escalation reached toxicity at 4, 5 and 6 mg/kg
Twenty-three children were enrolled between 1 September 2022 and 5 March 2025, and 20 were included in the primary analysis. All children in the primary analysis were recruited in Zambia; the three Kenyan participants were excluded because APTT measurements were unavailable, leaving them out of the continual reassessment model. Among those analyzed, the median age was 35 months, 60% were female, half had unrousable coma, and the median hemoglobin was 5.2 g/dL. Severe malarial anemia, deep acidotic breathing, and elevated lactate were all common at baseline, indicates how sick this cohort was before the first infusion even began.
The dose-escalation pathway moved from 1.5 mg/kg to 3 mg/kg, then to 4 mg/kg, 4.5 mg/kg, 5 mg/kg, and 6 mg/kg, following the continual reassessment model. Two dose-limiting toxicities emerged at 6 mg/kg after 14 children had been enrolled. The data monitoring committee then recommended de-escalation to 5 mg/kg, where both children developed dose-limiting toxicity, followed by 4 mg/kg, where both children again crossed the prespecified APTT threshold. The final cohort at 3 mg/kg had no dose-limiting toxicity, and that dose became the maximum tolerated dose for future investigation.
The toxicity signal was laboratory-defined rather than clinical. APTT above 95 seconds, 2.5 times the upper limit of normal, was the stopping rule, and the recorded abnormalities were usually between greater than 95 and less than 110 seconds. Only one child, who received 5 mg/kg, had an APTT above 110 seconds. No bleeding events accompanied these changes. The coagulation effect was therefore measurable, reversible in practice, and clinically silent in this cohort.
Coagulation changes emerged without bleeding complications
The absence of overt hemorrhage is the most reassuring part of the safety picture. In a severely ill pediatric malaria population, any anticoagulant effect raises immediate concern, because anemia, capillary leak, cerebral involvement, and multiorgan dysfunction can already destabilize patients. Here, the laboratory signal did not translate into bedside bleeding, and at 24 hours the overall mean APTT had returned to 36 seconds. The study design also matters: because the infusions were spaced 8 hours apart, the coagulation effect could be tracked over time rather than assumed from a single post-dose snapshot.
One child died, one child was readmitted, and one grade 3 non-dose-limiting adverse event occurred, consisting of fever and cough. The death and readmission were judged unrelated to sevuparin, and no neurological sequelae were reported at day 28. In addition, an expanded analysis that included all 23 enrolled children produced similar safety findings. A second readmission for convulsions appeared in that broader dataset, again without a clear causal link to the study drug.
Lactate fell, but the study was not built to prove clinical benefit
Lactate fell by a mean of 1.9 mmol/L in the 5- to 12-hour window around the second infusion, and the same absolute reduction was seen at 24 hours. Those numbers are directionally encouraging because lactate is a proxy for perfusion failure in severe malaria, but the trial was not powered to claim efficacy. In a disease defined by microvascular obstruction, a drop in lactate is biologically plausible if sequestration is loosened and tissue oxygen delivery improves. Still, the study leaves the effect size unresolved.
Parasite clearance half-life could be estimated in only five children because three parasitemia measurements were required for the calculation. In that small subset, the geometric mean parasite half-life was 6 hours. No mature infected erythrocytes were seen on microscopy at 9 or 24 hours. These observations are consistent with a drug that may alter parasite dynamics and microcirculatory behavior, but the sparse microscopy data prevent any strong inference.
What the phase I design did and did not answer
The trial’s primary purpose was dose finding, and it accomplished that goal. It established 3 mg/kg as the most appropriate dose for a future pediatric study and showed that higher doses produced APTT prolongation without clinical bleeding in this small cohort. It also suggested that lactate clearance at 8 hours is feasible to measure, which could make it a candidate endpoint for a later phase II trial.
What remains unresolved is whether the biological promise of a heparin-like anti-adhesion strategy can be translated into hard outcomes such as faster recovery, fewer neurological complications, or lower mortality. The present data cannot answer that question, because the study was single-arm, small, and designed around safety and dosing rather than comparative efficacy. The next step has to test whether the microvascular logic seen in the laboratory and at the bedside can move beyond transient biomarker change and into outcomes that matter to hospitalized children with severe malaria.
For now, the practical result is narrower but important: a pediatric dose has been identified, and the main safety concern was confined to a monitored laboratory abnormality rather than clinical hemorrhage. In severe malaria, that is enough to justify further study, but not enough to change standard care on its own.